Shots:
- Zonsen PepLib Biotech has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based radioligand therapy asset
- As per the deal, Novartis will obtain exclusive worldwide rights & lead the development & commercialization activities for the undisclosed asset
- In return, PepLib will receive $50M upfront, with additional development, regulatory, & sales milestone payments, & tiered royalties on future global net sales
Ref: PRnewswire  | Image: PepLib & Novartis |Press Release
Related News: SciNeuro Forges ~$1.7B Deal with Novartis to Advance Therapeutics for Alzheimer’s Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
